Medpagetoday: By Crystal Phend, Senior Staff Writer, MedPage Today Published: March 13, 2012
Using hemoglobin A1c (HbA1c) to catch prediabetes may be cost-effective if the threshold for diagnosis set at 5.7%, according to an analysis led by the CDC.
The cost of treating patients for an HbA1c level less than 5.7% would likely outweigh the savings from improvement in long-term outcomes, according to an analysis by Xiaohui Zhuo, PhD, of the CDC in Atlanta, and colleagues largely at the same agency.
hose diagnostic cutoffs wouldn’t fall within the $50,000 per quality life-year gained, typically considered cost-effective, they reported in the April issue of the American Journal of Preventive Medicine. Read More